| Category . | CG (%) . | Tip-lesion FSGS (%) . | P-value . |
|---|---|---|---|
| Total number of cases | 321 | 51 | |
| ‘Sole', n (%) | 170 (53) | 37 (73) | <0.01 |
| ‘Accompanied', n (%) | 151 (47) | 14 (28) | |
| Vascular diseases,a n (%) | 84 (26) | 3 (6) | <0.01 |
| Severe AS | 38 (12) | 2 (4) | 0.09 |
| Diabetic nephropathy | 20 (6) | 1 (2) | 0.22 |
| Severe AS + diabetic nephropathy | 12 (4) | 0 | NA |
| TMA | 14 (4) | 0 | NA |
| Nonvascular diseases,a n (%) | 67 (21) | 11 (22) | 0.94 |
| MGN | 21 (7) | 5 (10) | 0.45 |
| Lupus nephropathy | 20 (6) | 1 (2) | 0.22 |
| IgA nephropathy (proliferative) | 4 (1) | 0 | NA |
| Other nonvascular diseases | 22 (7) | 5 (10) | 0.16 |
| Category . | CG (%) . | Tip-lesion FSGS (%) . | P-value . |
|---|---|---|---|
| Total number of cases | 321 | 51 | |
| ‘Sole', n (%) | 170 (53) | 37 (73) | <0.01 |
| ‘Accompanied', n (%) | 151 (47) | 14 (28) | |
| Vascular diseases,a n (%) | 84 (26) | 3 (6) | <0.01 |
| Severe AS | 38 (12) | 2 (4) | 0.09 |
| Diabetic nephropathy | 20 (6) | 1 (2) | 0.22 |
| Severe AS + diabetic nephropathy | 12 (4) | 0 | NA |
| TMA | 14 (4) | 0 | NA |
| Nonvascular diseases,a n (%) | 67 (21) | 11 (22) | 0.94 |
| MGN | 21 (7) | 5 (10) | 0.45 |
| Lupus nephropathy | 20 (6) | 1 (2) | 0.22 |
| IgA nephropathy (proliferative) | 4 (1) | 0 | NA |
| Other nonvascular diseases | 22 (7) | 5 (10) | 0.16 |
Evaluated in the total study cohorts of CG (n = 321) and tip-lesion FSGS (n = 51).
‘Vascular diseases’ refers to the sum of the four diagnoses listed in this table. ‘Other diseases’ refers to all other ‘nonvascular’ diagnoses (bold indicates statistically significant higher incidence of P-value).
| Category . | CG (%) . | Tip-lesion FSGS (%) . | P-value . |
|---|---|---|---|
| Total number of cases | 321 | 51 | |
| ‘Sole', n (%) | 170 (53) | 37 (73) | <0.01 |
| ‘Accompanied', n (%) | 151 (47) | 14 (28) | |
| Vascular diseases,a n (%) | 84 (26) | 3 (6) | <0.01 |
| Severe AS | 38 (12) | 2 (4) | 0.09 |
| Diabetic nephropathy | 20 (6) | 1 (2) | 0.22 |
| Severe AS + diabetic nephropathy | 12 (4) | 0 | NA |
| TMA | 14 (4) | 0 | NA |
| Nonvascular diseases,a n (%) | 67 (21) | 11 (22) | 0.94 |
| MGN | 21 (7) | 5 (10) | 0.45 |
| Lupus nephropathy | 20 (6) | 1 (2) | 0.22 |
| IgA nephropathy (proliferative) | 4 (1) | 0 | NA |
| Other nonvascular diseases | 22 (7) | 5 (10) | 0.16 |
| Category . | CG (%) . | Tip-lesion FSGS (%) . | P-value . |
|---|---|---|---|
| Total number of cases | 321 | 51 | |
| ‘Sole', n (%) | 170 (53) | 37 (73) | <0.01 |
| ‘Accompanied', n (%) | 151 (47) | 14 (28) | |
| Vascular diseases,a n (%) | 84 (26) | 3 (6) | <0.01 |
| Severe AS | 38 (12) | 2 (4) | 0.09 |
| Diabetic nephropathy | 20 (6) | 1 (2) | 0.22 |
| Severe AS + diabetic nephropathy | 12 (4) | 0 | NA |
| TMA | 14 (4) | 0 | NA |
| Nonvascular diseases,a n (%) | 67 (21) | 11 (22) | 0.94 |
| MGN | 21 (7) | 5 (10) | 0.45 |
| Lupus nephropathy | 20 (6) | 1 (2) | 0.22 |
| IgA nephropathy (proliferative) | 4 (1) | 0 | NA |
| Other nonvascular diseases | 22 (7) | 5 (10) | 0.16 |
Evaluated in the total study cohorts of CG (n = 321) and tip-lesion FSGS (n = 51).
‘Vascular diseases’ refers to the sum of the four diagnoses listed in this table. ‘Other diseases’ refers to all other ‘nonvascular’ diagnoses (bold indicates statistically significant higher incidence of P-value).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
